COMP <GO>
NKLR vs CUVL // EV/EBITDA & P/E VALUATION
Terra Innovatum Global N.V. (NASDAQ) VS. Clinuvel Pharmaceuticals Limited (NASDAQ) • 15-METRIC TALLY: NKLR 0
— CUVL 5
■ METRIC PARITY
LAST: $2.22 (-4.72%) • MKT CAP: $257.5M
valuation
—
LAST: $5.07 (-1.55%) • MKT CAP: $257.8M
valuation
9.7x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NKLR VS. CUVL)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NKLR | CUVL | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 81.20% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 9.7x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -4.00% | 10.51% | -14.51 | CUVL | /fcf-yield <GO> |
| Operating Margin | — | 43.40% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 37.80% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 5.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.66% | -0.66 | CUVL | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 6/9 | -3.00 | CUVL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 34.5 | 41.2 | -6.70 | CUVL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 10.3x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $257.5M | $257.8M | -$345.5K | CUVL | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NKLR REV | CUVL REV | NKLR GROSS % | CUVL GROSS % | NKLR FCF | CUVL FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $61.1M | — | 81.2% | -$10.3M | $27.1M |
| FY 2024 | $0 | $57.9M | — | 81.5% | -$42.0K | $20.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NKLR // BETA —
CUVL // BETA —